Opinion
Video
Neoadjuvant Approaches in HER2+ Breast Cancer
Experts discuss evidence-based strategies in neoadjuvant therapy for HER2+ breast cancer and provide insights on surgery-first considerations, disease size impact, and personalized preoperative regimens.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
The panel delves into evidence-based approaches for patients with HER2-positive breast cancer in the neoadjuvant setting. Rugo emphasizes tailoring treatments based on tumor size, hormone receptor status, and patient age. The discussion navigates the decision-making process regarding surgery vs preoperative therapy, with consensus around a 1.5-cm threshold for initiating neoadjuvant treatment. The experts address nuances, emphasizing the need for accurate tumor staging and utilizing imaging, especially MRI, to inform decisions. Rugo underscores the challenge of balancing adequate treatment without overtreating small, node-negative cancers. The conversation touches on ongoing trials such as the CompassHER2-pCR study and highlights the role of age in treatment decisions. The panel provides valuable insights into the complexities of neoadjuvant therapy, offering guidance for optimizing outcomes in patients with HER2-positive breast cancer.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
